NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced .
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 414,500 shares, an increase of 28.7% from the May 15th total of 322,100 shares. Currently, 0.7% of the shares of the stock are sold short. Based on […]
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) traded up 0.9% during mid-day trading on Wednesday . The company traded as high as $3.55 and last traded at $3.48. 53,116 shares changed hands during trading, a decline of 39% from the average session volume of 87,693 shares. The stock had previously closed at $3.45. Wall Street […]